MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/ejh.14148

Медицинская библиотека · European journal of haematology · 2023

Rituximab with standard LMB chemotherapy in pediatric high-risk mature B-cell non-Hodgkin lymphoma: A report from the JPLSG B-NHL14 trial.

Mori Tetsuya, Osumi Tomoo, Kada Akiko, Ohki Kentaro, Koga Yuhki, Fukano Reiji, Fujita Naoto, Mitsui Tetsuo, Mori Takeshi, Saito Akiko M, Nakazawa Atsuko, Kobayashi Ryoji, Sekimizu Masahiro

Клиническое исследование III фазыРандомизированное исследованиеМногоцентровое исследованиеСтатьяПеревод в очереди

Аннотация

BACKGROUND

The benefit of adding rituximab to standard lymphomes malins B (LMB) chemotherapy for children with high-risk mature B-cell non-Hodgkin lymphoma (B-NHL) has previously been demonstrated in an international randomized phase III trial, to which the Japanese Pediatric Leukemia/Lymphoma Study Group could not participate.

METHODS

To evaluate the efficacy and safety of rituximab in combination with LMB chemotherapy in Japanese patients, we conducted a single-arm multicenter trial.

RESULTS

In this study, 45 patients were enrolled between April 2016 and September 2018. A total of 33 (73.3%), 5 (11.1%), and 6 (13.3%) patients had Burkitt lymphoma/leukemia, diffuse large B-cell lymphoma, and aggressive mature B-NHL, not otherwise specified, respectively. Ten (22.2%) and 21 (46.7%) patients had central nervous system disease and leukemic disease, respectively. The median follow-up period was 47.5 months. Three-year event-free survival and overall survival were 97.7% (95% confidence interval, 84.9-99.7) and 100%, respectively. The only event was relapse, which occurred in a patient with diffuse large B-cell lymphoma. Seven patients (15.6%) developed Grade 4 or higher non-hematologic adverse events. Febrile neutropenia was the most frequent Grade 3 or higher adverse event after the pre-phase treatment, with a frequency of 54.5%.

CONCLUSION

The efficacy and safety of rituximab in combination with LMB chemotherapy in children with high-risk mature B-NHL was observed in Japan.

Для цитирования: Mori Tetsuya, Osumi Tomoo, Kada Akiko, Ohki Kentaro, Koga Yuhki, Fukano Reiji, Fujita Naoto, Mitsui Tetsuo, Mori Takeshi, Saito Akiko M, Nakazawa Atsuko, Kobayashi Ryoji, Sekimizu Masahiro. Rituximab with standard LMB chemotherapy in pediatric high-risk mature B-cell non-Hodgkin lymphoma: A report from the JPLSG B-NHL14 trial.. European journal of haematology. 2023. DOI: 10.1111/ejh.14148.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.